先端医療シリーズ18 脳腫瘍の最新医療

書籍・雑誌
≪全国送料無料でお届け≫
品切れ

13,619 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,810 円(税込)

商品紹介

このたび先端医療シリーズ第18巻として、「脳腫瘍の最新医療」を刊行する運びとなった。脳腫瘍の診断と治療法は、近年目覚しい発展を遂げており、脳神経外科医は常にその進歩の現状を熟知していることが望まれる。本書には、脳腫瘍画像診断、検査法の進歩から遺伝子治療、細胞療法など最近の知見迄、それぞれの分野で実際に研究されている方々に現状を紹介して頂いたので、それぞれの項目について最も新しい情報を知ることができる。

目次

  • 先端医療シリーズ 18 脳腫瘍の最新医療

    ― 目次 ―

    序 文…………………………………………………………??匕?
    序 章
    脳腫瘍の新しい治療法………………………………………野村和弘
    第1章 遺伝子治療
    1.遺伝子治療の展望………………………………………吉田 純
    2.インターフェロン遺伝子治療…………………………若林俊彦
    3.単純ヘルペスウイルスを用いた遺伝子治療…………藤堂具紀
    4.免疫遺伝子治療…………………………………………岡田秀穂
    5.自殺遺伝子治療…………………………………………清水惠司
    6.アデノウイルスベクターを用いた遺伝子治療………梶原浩司
    7.アデノ随伴ウイルスを用いた遺伝子治療……………水野正明
    第2章 細胞療法
    1.細胞療法の展望とガイドライン………………………平家勇司
    2.樹状細胞療法……………………………………………菊池哲郎
    3.同種骨髄移植……………………………………………田中 実
    4.神経幹細胞を用いた複合療法…………………………矢崎貴仁
    5.胚性幹細胞療法…………………………………………本望 修
    6.ミクログリアを用いた脳腫瘍の細胞療法……………澤田 誠
    第3章 分子標的療法
    1.分子標的療法の展望……………………………………鶴尾 隆
    2.脳腫瘍の分子標的………………………………………牧野敬史
    3.単鎖抗体を用いた療法………………………………高須俊太郎
    4.モノクローナル抗体を用いた脳腫瘍抗体療法………三島一彦
    5.オリゴペプチドを用いた療法…………………………上羽哲也
    第4章 免疫療法
    1.免疫療法の展望…………………………………………珠玖 洋
    2.TIL/LAK療法……………………………………中原紀元
    3.腫瘍ワクチン療法………………………………………戸田正博
    4.生物学的免疫応答………………………………………高橋 弘
    5.サイトカイン療法………………………………………菊池哲郎
    第5章 化学療法
    1.化学療法の展望…………………………………………西條長宏
    2.グリオーマの「テーラーメイド」治療へ向けて……植木敬介
    3.小児悪性脳腫瘍に対する超大量化学療法……………原 純一
    4.悪性リンパ腫に対するMTX大量化学療法…………… 泉本修一
    5.管新生阻害剤……………………………………………吉田大蔵
    6.転位抑制剤………………………………………………竹島秀雄
    7.脳血液関門破壊化学療法………………………………池?垣郷
    8.プロテオミクスによる腫瘍感受性因子検索…………岩立康男
    第6章 放射線治療
    1.放射線治療の展望………………………………………丸野元彦
    2.ガンマナイフ……………………………………………中村克巳
    3.直線加速器を用いた定位放射線照射…………………白土博樹
    4.マイクロマルチリーフ照射……………………………中川秀光
    5.強度変調放射線療法……………………………………芝本雄太
    6.中性子捕捉療法…………………………………………松村 明
    7.重粒子線治療……………………………………………溝江純悦
    第7章 温熱療法
    1.温熱療法:最近の進歩…………………………………田中隆一
    2.RF組織内温熱療法……………………………………高橋英明
    3.マグネトリポソームを用いた温熱免疫療法…………若林俊彦
    4.レーザー温熱療法………………………………………厚見秀樹
    第8章 切除率の向上のための新技術
    1.新技術の展望……………………………………………嘉山孝正
    2.蛍光色素を用いたグリオーマ手術……………………黒岩敏彦
    3.神経膠腫摘出における皮質下電気刺激法……………隈部俊宏
    4.覚醒下手術(脳機能マッピング)……………………村垣善浩
    第9章 ナビゲーション手術とロボット手術
    1.脳腫瘍外科におけるナビゲーション手術……………渡辺英寿
    2.ナビゲーターによる頭蓋底腫瘍の治療………………大平貴之
    3.ナビゲーションによる内視鏡手術……………………黒木 亮
    4.超音波ナビゲーション…………………………………森竹浩三
    5.脳神経外科におけるロボット手術……………………奥寺 敬
    第10章 画像診断・検査
    1.脳腫瘍の画像診断………………………………………興梠征典
    2.拡散強調画像を利用した神経線維の追跡……………山田 惠
    3.MRS……………………………………………………中村克巳
    4.MDCT………………………………………………佐々木真理
    5.脳腫瘍の分化および予後に関連した腫瘍マーカー…白石哲也
    第11章 治療薬に関する最新情報
    1.Temozolomideについて…………………………………青木友和
    2.頭蓋内圧亢進治療薬……………………………………臼井雅昭
    3.抗痙攣薬…………………………………………………臼井雅昭
    第12章 各種製品の臨床評価
    1.サイバーナイフ 脳・頸髄領域腫瘍の治療…………荻田幹夫
    2.フェロン の脳腫瘍治療への適用…………………… 川瀬 司
    3.X線透過多目的ヘッドフレームの開発………………奥寺 敬

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章

P.5 掲載の参考文献
3) The committee of brain tumor registry of Japan:Report of brain tumor registry of Japan (1969-19939 Neurologia medico-chirurgica, Supplement Vol.40:34-92, 2000
4) 野村和弘:神経膠腫の標準的治療の確率に関する研究. 厚生労働省がん研究助成金による研究報告集, 平成12年度:国立がんセンター, 東京 P361-366, 2000
8) Marks JE, et al:Cerebral Radionecrosis:Incidence and risk in relation to dose, time, fractionaization and volume. Int J radiat Oncol Biol Phys 7:243-252, 1981
9) Shaw EG:The low-grade glioma debate:evidence defending the position of early radiation therapy. Clin Neurosurg 42:488-494, 1995
11) Karim AB, Afra D, Cornu P, et al:Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult:European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4:an interim analysis. 52
17) 水野正明, 吉田 純:ポストゲノム医療の展望と将来:各論遺伝子治療の現状と将来, 脳腫瘍. 日本臨床59:76-80, 2001

第1章 遺伝子治療

P.11 掲載の参考文献
1) Journal of Gene Medicine 誌ホームページ:http://www.wiley.co.uk/genetherapy/
2) 厚生労働省ホームページ;審議会議事録:遺伝子治療臨床研究の在り方に関する委員会合同会合資料 http://www.mhlw.go.jp/shingi/0107/s0731-2.html
3) 厚生労働省ホームページ;審議会議事録:厚生科学審議会科学技術部会がん遺伝子治療臨床研究作業委員会の概要 http://www.mhlw.go.jp/shingi/2002/04/s1412-1.html
4) 厚生労働省ホームページ;審議会議事録:厚生科学審議会科学技術部会小児免疫不全疾患遺伝子治療臨床研究作業委員会の議事要旨 http://www.mhlw.go.jp/shingi/2002/04/s1416-2.html
5) 厚生労働省ホームページ;審議会議事録:厚生科学審議会冠動脈疾患遺伝子治療臨床研究作業委員会・科学技術・学術審議会遺伝子治療臨床研究 (冠動脈疾患) 審査ワーキンググループの概要 http://www.mhlw.go.jp/shingi/2002/02/s0215-1.html
6) 厚生労働省ホームページ;審議会議事録:厚生科学審議会がん遺伝子治療臨床研究作業委員会・科学技術・学術審議会遺伝子治療臨床研究 (がん) 審査ワーキンググループの議事要旨 http://www.mhlw.go.jp/shingi/0111/s1114-3.html
7) 厚生労働省ホームページ;審議会議事録:従来の「遺伝子治療臨床研究に関する指針」からの改正点の概要 http://www.mhlw.go.jp/shingi/0112/s1211-2g.html
8)文部科学省・厚生労働省告示第一号;遺伝子治療臨床研究に関する指針
P.16 掲載の参考文献
6) Tashiro T, Yoshida J, Mizuno M, Sugita K:Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-α gene. J Neorusurg 78:252-256, 1993
14) 頃末和良, 玉木紀彦, 松本悟, ほか:脳腫瘍治療に於けるインターフェロンと放射線照射併用療法に関する基礎的研究. Neurol Med Chir 24:233-239, 1984
18) Mizuno M, Yoshida J, Sugita K, et al:Growth inhibition of glioma cells transfected with the human β-interferon gene by liposome coupled with a monoclonal antibody. Cancer Res 50:7826-7829, 1990
19) Yoshida J, Mizuno M, Yagi K:Cytotoxicity of human βinterferon produced in human glioma cells transfected with its gene by means of liposomes. Biochem. Int 28:1055-1061, 1992
20) Mizuno M, Yoshida J, Sugita K, Inoue I, Seo H, Hayashi Y, Koshizuka T, Yagi K:Growth inhibition of glioma cells transfected with the human β-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 50:7826-7829, 1990
22) Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J:IFN-beta therapy induces systemic antitumor immunity against malignant glioma. J Neuro-Oncol 47:117-124, 2000
P.23 掲載の参考文献
13) Nakamura H, Mullen J T, Chandrasekhar S, et al:Multimodality therapy with a replication conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 61:5447-5452, 2001
15) Yamamura H, Hashio M, Noguchi M, et al:Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 61:3969-3977, 2001
16) Nakamura H, Kasuya H, Mullen J T, et al:Regulation of herpes simplex virus γ1 34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J CIin Invest 109:871-882, 2002
17) Fu X, Zhang X:Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytialphenotype. Cancer Res 62:2306-2312, 2002
P.29 掲載の参考文献
1) Okada H, et al:Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther 3:957-964, 1996
7) Wakimoto H, et al:Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56:1828-1833, 1996
8) Okada H, Lotze MT:Rosenberg SA, editors. Principles and Practice of the Biologic Therapy of Cancer. 3rd Edition ed. Silverchair, Science + Communications Inc;Interleukin-4:Clinical Applications. p. 93-102, 2000
10) Schuler T, et al:TH1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in IL-4-deficient mice. J Exp Med 189:803-810, 1999
12) Giezeman-Smits KM, et al:Cytokine gene therapy of gliomas:Induction of reactive CD4 + T cells by interleukin-4 transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60:2449-2457, 2000
13) Okada H, et al:Gene therapy of malignant gliomas:a phase I study of IL4HSV-TK genemodified autologous tumor to elicit an immune response (clinical protocol) . Human Gene Ther 11:637-653, 2000
15) Okada H, et al:Interleukin-4 gene transfected autologous tumor cell vaccine in the treatment of recurrent glioblastoma:Preliminary observations in a patient with a favorable response to therapy. J Neurooncol in press2002
18) Kalinski P, et al:T-cell priming by type-1 and type-2 polarized dendritic cells:the concept of a third signal. [Review] [80 refs]. Immunol. Today 20:561-567, 1999
20) Nishioka Y, et al:Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59:4035-4041, 1999
P.37 掲載の参考文献
1) 脳腫瘍全国集計調査報告. Neurol Med Chir (Tokyo), 10:40 (Suppl), 2000
3) Green SB, Byar DP, Walker MD, et al:Comparisons of Carmustine, Procarbazine, and high-dose Methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67:121-132, 1983
7) Markowitz D, Goff S, Bank A:Asafe packaging line for gene transfer. Separating viral genes on two different plasmids. J Virol 62:1120-1124, 1988
9) Yee J-K:Retroviral Vectors, Friedmann T:The Development of Human Gene Therapy, Cold Spring Harbor Laboratory Press, New York, p21-45, 1999
10) Sorrentino BP, Nienhuis AW:T he hematopoietic system as atarget for gene therapy, Friedmann T:The Development of Human Gene Therapy, Cold Spring Harbor Laboratory Press, New York, p351-426, 1999
31) Ohtomo T, Kawata Y, Sekimori Y, et al:A humanized single-chain Fv fragment with high targeting potential against human malignant gliomas. Anticancer Res 18:4311-4315, 1998
P.42 掲載の参考文献
1) Summary Table:Human Gene Therapy Protocols, Last Updated 2/14/02. Hum Gene Ther 13:1001-1002, 2002
6) Byrnes AP, Wood MJA, Charlton HM:Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther 3:644-651, 1996
7) Ideguchi M, Kajiwara K, Yoshikawa K, et al:Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. Neuroscience 95:217-226, 2000
8) Byrnes AP, Maclaren RE, Charlton HM:Immunological instability of persistent adenovirus vectors in the brain:Peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 16:3045-3055, 1996
9) Ohmoto Y, Wood MJA, Charlton HM, et al:Variation in the immune response to adenoviral vectors in the brain:influence of mouse strain, environmental conditions and priming. Gene Ther 6:471-481, 1996
10) 齋藤泉:アデノウイルスベクター, 谷憲三郎・浅 野茂隆編集:遺伝子治療の新展開, 羊土社, 東京, p21-36, 2001
12) Peter-Cruet MJ, Trask TW, Chen SH, et al:Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 39:506-511, 1994
14) Morioka J, Kajiwara K, Yoshikawa K, et al:Adenovirus-mediated gene transfer of B7. 1 inducesimmunological anti-tumor effects in a murine brain tumor. J Neurooncol (in press)
15) Cirielli C, Inyaku K, Capogrossi MC, et al:Adenovirus-mediated wild type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J Neurooncol 43:99-108, 1999
18) Tanaka T, Cao Y, Folkman J, et al:Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58:3362-3369, 1998
20) Journal of Gene Medicine (http://www.wiley.co.-uk/genetherapy/clinical/index.html) インターネット公開資料より
P.50 掲載の参考文献
16) Yoshida J, et al:Antitumor effect of an adeno-associated virus vector containing the human interferon-β gene on experimental intracranial human glioma. Jpn J Cancer Res 93:223-228, 2002

第2章 細胞療法

P.53 掲載の参考文献
1) Turnheim, D:The OECD policy for the implementation of the principles of good laboratory practice. Annali Dell' Istituto Superiore di Sanita 30 (4):395-400, 1994
2) http://webnet1.oecd.org/EN/home/0,,EN-home-526-14-no-no-no-0,00.html
3) Anonymous, Nonclinical laboratory studies:good laboratory practice regulations. Federal Register 43 (247):59985-60025, 1978
4) http://www.fda.gov/ora/compliance_ref/bimo/default.htm
5) http://www.kiko.go.jp/inquire/inquire.html
6) http://www.jsqa.com/content.htm
7) http://www.est.hi-ho.ne.jp/atk-uno/page007.html
9) Anonymous, Current good mamfacturing practice in manufacturing, processing, packing, or holding of drugs;revision of certain labeling controls-FDA. Final rule. Federal Register 58 (147):41348-41354, 1993
10) Anonymous, Mutual recognition of pharmaceutical good manufacturing practice inspection reports, medical device quality system audit reports, and certain medical device product evaluation reports between the United States and the European Community-FDA. Final rule. Federal Register 63 (215):60122-60164, 1998
11) http://www.fda.gov/cdrh/devadvice/32.html
13) Ways JP, Preston, MS, Baker D, et al:Good manufacturing practice (GMP) compliance in the biologics sector:plasma fractionation. Biotechnology & Applied Biochemistry 30 (Pt 3):257-265, 1999
15) Anonymous, Biological products:reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule. Federal Register 65 (216):66621-66635, 2000
16) http://www.fda.gov/oc/gcp/default.htm
17) http://jcogweb.res.ncc.go.jp/
19) Dixon JR, Jr:The International Conference on Harmonization Good Clinical Practice guideline. Quality Assurance 6 (2):65-74, 1998
20) http://www.nihs.go.jp/dig/ich/ichindex.htm
21) http://www.fda.gov/cber/
22) http://www.fda.gov/cder/
23) http://www.wjtog.org/
24) http://www.csp.or.jp/
25) http://www/crsu.org/
26) http://sct.umin.jp/
27) http://www.archives.gov/federal_register/index.html
P.59 掲載の参考文献
2) 稲葉カヨ, 稲葉宗夫:樹状細胞の生物学的特性. 最新医学 14:2604-2611, 1999
10) Insug O, et al:A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613-621, 2002
12) Ni HT, et al:Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1-9, 2001
14) Lopez JA, Hart DNJ:Current issues in dendritic cell cancer immunotherapy. Curr Opin Mol Ther 4:54-63, 2002
16) Yu JS, et al:Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001
P.65 掲載の参考文献
1) Wekerele H, Sun D, Oropeza-Wekerle RL, et al:Immune reactivity in the nervous system:modulation of T-lymphocyte activation by glialcells. J Exp Biol 132:43-57, 1987
2) Yu JS, Wheeler CJ, Zeltzer PM, et al:Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicitiy and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001
6) Okamoto T, Kanamaru A, Shimazaki C, et al:Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG):results of an interim analysis. Int J Hematol 72:200-205, 2000
8) Morishima Y, Kodera Y, Hirabayashi N, et al:Low incidence of acute GVHD in patients transplanted with marrow from HLA-A, B, DR-compatible unrelated donors among Japanese. Bone Marrow Transplant 15:235-239, 1995
9) Horowitz MM, Gale RP, Sondel PM, et al:Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
12) Von der Harst D, Goulmy E, Falkenburg JH, et al:Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83:1060-1066, 1994
13) Gaugler B, Van den Eynde B, Van der Bruggen P, et al:Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930, 1994
14) Boel P, Wildmann C, Sensi ML, et al:BAGE:a new gene encoding an antigen recognized on human melanomas by cytolytic lymphocytes. Immunity 2:167-175, 1995
15) Wolf SF, Temple PA, Kobayashi M, et al:Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074-3081, 1991
16) Watanabe-Fukunaga R, Brnman CI, Itoh N, et al:The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148:1274-1279, 1992
17) Tsujimoto M, Vip YK, Vilcek J:Interferon-γ enhances expression of cellular receptors for tumor necrosis factor. J Immunol 136:2441-2444, 1986
19) Truitt RL, Shih CY, Lefever AV, et al:Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol 131:2050-2058, 1983
P.71 掲載の参考文献
P.75 掲載の参考文献
3) Tanooka A, et al:Transplantation of the embryonic stem cells into the ischemic brain. Restorative Neurology and Neuroscience 2002, in press.
4) 田之岡 篤ほか:「胚性幹細胞の脳梗塞モデルへの移植」神経の再生. 脳の科学2002, in press
5) Oka S, et al:Fate of the transplanted embryonic stem cells in the demyelinated spinal cord. Restorative Neurology and Neuroscience 2002, in press.
6) Oka S, et al:Mouse embryonic stem cells remyelinate demyelinated axons in the adult rat spinal cord. Abst. Society for Neuroscience, 2001
7) 佐々木祐典ほか:「中枢性脱髄疾患に対する胚性幹細胞・骨髄の移植」神経の再生. 脳の科学 2002, in press
16) 本望修, 上出廷治, 端和夫:神経幹細胞応用の可能性について. 脳神経外科29:293-304, 2001
17) 佐々木祐典, 本望 修:「細胞治療~再生医療への展開」神経幹細胞移植. 最新医学12:2666-2670, 2001
18) 島崎琢也:神経幹細胞を用いた再生医学, 横田 崇編集:再生医学がわかる, 羊土社, 東京, p76-83, 2002
19) 西村文彦ほか:胚性幹細胞を用いたマウス Parkinson 氏病モデルの治療の試み. 第61回日本脳神経外科学会総会抄録, 2002
20) Honmou O, et al:Studies of myelin formation after transplantation of MHC knockout mouse Schwann cells into the demyelinated rat spinal cord. Abst Soc Neurosci, 1998
P.82 掲載の参考文献
1) Hortega P. del Rio:In Cytology and Cellular Pathology of the Nervous System, ed. W. Penfield Vol. 2, pp. 483-534, Hoeber, 1932
9) 澤田誠:脳のサイトカインネットワーク, 蛋白質核酸酵素42:504-511, 1997
13) Finsen B, Lehrmamn E, Castellano B, et al:The role of microglia and brain macrophages in transient global cerebral ischaemia. In Topical issues in microglia research, eds. EA Ling, CK Tan, CBC Tan, pp. 297-318, Goh Bros. Enterprise Humanities Press, 1996
15) Sawada M, Imai F, Suzuki H, et al:Brain specific migration and protective roles in ischemic brainlesion of microglia. Rev Neurol IVth Eur Meeting of Glial Cell Function in Health and Disease 78:2000
16) 澤田誠:ミクログリアの新規な性質と脳での役割ミクログリアは脳でなにをしているか. 細胞工学 18:550-558, 1999
21) Frei K, Siepl C, Bodmer S, et al:Antigen presentation and tumor cytotoxicity by interferon-γ-treated microglia cells. Eur J Immunol 17:1271-1278, 1987
25) Flugel A, Labeur MS, Grasbon-Frodl EM, et al:Microglia only weakly present glioma antigen to cytotoxic T cells. Int J Dev Neurosci 17:547-556, 1999

第3章 分子標的療法

P.91 掲載の参考文献
1) Vogel C, Cobleigh M, Tripathy D, et al:First-line, nonhormonal treatment of woman with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 19:71a (abstr275), 2000
5) Burstein HJ, Kulter I, Campos SM, et al:Clinical activity of trastuzumab and vinorelbine in woman with HER2 overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
10) Moulder SL, Yakes FL, Muthuswamy SK, et al:Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vitro. Cancer Res 61:8887-8895, 2001
11) Christensen JG, Schreck RE, Chan E, et al:High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in Vitro. Clin Cancer Res 7:4230-4238, 2001
13) Chan KC, Knox WF, Gee JM, et al:Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 62:122-128, 2002
15) Nakagawa K, Yamamoto N, Kudoh S, et al:A phase I intermittent dose-escalation trial of ZD 1839 (Iressa) in Japanese patients with solid malignat tumours. Proc ASCO 19:183a, 2000
16) Guputa S and Tsuruo T:Multidrug resistance in cancer cells Guputa S, Tsuruo T (eds) John Wiley&Sons Ltd, West Sussex, pp.1-507, 1996
19) Sakamoto H, Mashima T, Kizaki A, et al:Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 95:3214-3218, 2000
20) Sakamoto H, Mashima T. Sato, S, et al:Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clinical Cancer Res 7:2513-2518, 2001
21) Ogiso Y, Tomida A, Lei S, et al:Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 60:2429-2434, 2000
22) 16) 遺伝子医学新世紀医療をめざして-SNPとDNAチップ. 4:1, 2000
P.98 掲載の参考文献
8) Haas-Kogan D, et al:Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8:1195-1198, 1998
9) Nakashio A, et al:Prevention of phosphatidy-linositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60:5303-5309, 2000
14) Kunkel P, et al:Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624-6628, 2001
16) Mikecz K:Vitaxin applied molecular evolution Curr Opin Investig Drugs 1:199-203, 2000
P.102 掲載の参考文献
2) Kohler G, Milstein C:Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495-497, 1975
3) Nadler LM, Stashenko P, Hardy R, et al:Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147-3154, 1980
5) Bird RE, Hardman KD, Jacobson JW, et al:Single-chain antigen-binding Proteins. Science 242:423-426, 198
8) Wels W, Harwerth IM, Mueller M, et al:Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52:6310-6317, 1992
9) Pavlinkova G, Booth BJ, Batra SK, et al:Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin Cancer Res 5:2613-2619, 1999
10) Park JW, Hong K, Kirpotin DB, et al:Anti-HER2 immunoliposomes:enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181, 2002
11) Khare PD, Shao-Xi L, Kuroki M, et al:Specificallytargeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res 61:370-375, 2001
13) Holliger P, Manzke O, Span M, et al:Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 xanti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 59:2909-2916, 1999
15) 渋谷正史:脳腫瘍における EGF 受容体遺伝子の異常. 脳神経 50:519-527, 1998
16) Kuan CT, Reist CJ, Bigner DD, et al:1251-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targetingof glioma xenografts. Clin Cancer Res 5:1539-1549, 1999
17) Archer GE, Sampson JH, Bigner DD, et al:Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 5:2646-2652, 1999
P.110 掲載の参考文献
2) Frankel AE:New HER2-directed therapies for breast cancer. Clin Cancer Res 8:1699-1701, 2002
7) Bergman I, Barmada MA, Griffin JA, et al:Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Clin Cancer Res 7:2050-2056, 2001
9) Ciardiello F, Tortora G:A novel approach in the treatment of cancer:Targeting the epidermal growth factor receptor. Clin. Cancer Res 7:2958-2970, 2001
11) Wersall P, Ohlsson I, Biberfeld P, et al:Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 44:157-164, 1997
12) Brady LW:A new treatment for high grade gliomas of the brain. Bull Mem Acad R Med Belg 153, 255-261, 1998
16) Mishima K, Johns TG, Luwor RB, et al:Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61:5349-5354, 2001
17) Luwor RB, Johns TG, Murone C, et al:Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplifed epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61:5355-5361, 2001
19) Chen HX, Gore-Langton RE, Cheson BD:Clinical trials referral resource:Current clinical trials of theanti-VEGF monoclonal antibody bevacizumab. cology 15:1017-1026, 2001
21) Kunkel P, Ulbricht U, Bohlen P, et al:Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624-6628, 2001
22) Vose JM:Antibody-targeted therapy for low-gradelymphoma. Semin Hematol 36:15-20, 1999
24) Czuczman MS, Grillo-Lopez AJ, White CA, et al:Treatment of patients with low-grade B-cell 110
25) Coiffier B, Haioun C, Ketterer N, et al:Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:amulticenter phase II study. Blood 92:1927-1932, 1998
36) 穀内 隆:脳腫瘍治療薬-抗TA226ヒト型モノクローナル抗体 (ACA-11). 日本臨床 60:100-106, 2002
37) 久保長生, 高倉公朋:脳腫瘍 Monoclonal immunotherapy with human monoclonal antibody (CLN-IgG) in glioma patients. 日本臨床 60:497-503, 2002
38) Archer GE, Sampson JH, Lorimer IA, et al:Regional treatment of epideumal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 5:2646-2652, 1999
39) Wallace PK, Romet-Lemonne J-L, Chokri M:Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecificantibody to FcγRI and the epidermal growth factor receptor. Cancer Immunol Immunother 49:493-503, 2000
40) Roy EJ, Cho BK, Rund LA, et al:Targeting T cells against brain tumors with a bispecific ligand-antibody coajugate. Int J Cancer 76:761-766, 1998
P.116 掲載の参考文献
1) Lamberts SWJ, Lely AJVD, Herder WW, et al:Octreotide New Engl J Med 334 (4):246-254, 1996
9) Fukumoto M, Takahashi J A, Murai N, et al:Induction of apoptosis in glioma cells:an approach to control tumor growth by blocking basic fibroblast growth factor autocrine loop. Anticancer Res 20:4059-4066, 2000
11) Kono K, Ueba T, Takahashi JA, et al:In vitro growth suppression of human glioma cells by a 16-mer oligopeptide:Apotential new treatment modality for malignant glioma (in submission)

第4章 免疫療法

P.122 掲載の参考文献
1) Boon T, et al:Cancer tumor antigens. Curr Opin Immunol 9:681-683, 1997
3) Nagata Y, et al:Peptides derived from a wild type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J lmmunol 159:1336-1343, 1997
4) Gu X-G, et al:A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immne responses against HER2 expressing murine sarcomas. Cancer Res 58:3385-3390, 1998
P.127 掲載の参考文献
4) Sawamura Y, Hosokawa M, Kuppner MC, et al:Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after invitro expansion in the presence of interleukin 2. Cancer Res 49:1843-1849, 1989
5) 中村博彦:養子免疫療法 LAK, 高倉公朋ほか監修:脳腫瘍の免疫と分子生物学, 金芳堂, 京都, p278-287, 1992
7) Quattrocchi KB, Miller CH, Cush S, et al:Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45:141-157, 1999
13) 中村博彦, 高倉公朋:悪性神経膠腫細胞の LAK 細胞に対する感受性に及ぼす化学療法剤, 放射線療法および温熱療法の影響. Biotherapy 6:727-730, 1992
18) 中村博彦, 設楽信行, 和田照美ほか:悪性脳腫瘍に対する局所養子免疫療法:Lymphokine-activated killer (LAK) 細胞の誘導と治療上の問題点について. Biotherapy 3:175-178, 1989
19) 沢村 豊, 細川真澄男, 小林 博ほか:担癌動物および担癌患者における養子移入 LAK 細胞の臓器分布. Biotherapy 2:163-167, 1988
22) Bohm M, Moller P, Kalbfleisch U, et al:Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. Br J Cancer 70:54-59, 1994
24) Gamero AM, Ussery D, Reintgen DS, et al:Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res 55:4988-4994, 1995
27) Kitai R, Zhao ML, Zhang N, et al:Role of MIP-1βand RANTES in HIV-1 infection of microglia:inhibition of infection and induction by IFNβ. J Neuroimmunol 110:230-239, 2000
28) Yamanaka R, Tanaka R, Yoshida S, et al:Suppression of TGF-β 1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. J Neurooncol 43:27-34, 1999
P.134 掲載の参考文献
1) Yu JS, Wheeler CJ, Zeltzer PM, et al:Vaccination of alignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001
5) Okada H, Pollack IF, Lotze MT, et al:Gene therapy of malignant gliomas:a phase I study of IL4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 11:637-653, 2000
7) Moore AE:The oncolytic viruses. Prog. Exp. Tumor Res 1:411-439, 1960
14) Nestle FO, Alijagic S, Gilliet M, et al:Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
21) 戸田正博:免疫系に認識されるグリオーマ抗原, 奥村康, 平野俊夫, 佐藤昇士監修:Annual Review 免疫中外医学社, 東京, 印刷中
22) Imaizumi T, Kuramoto T, Matsunaga K, et al:Expression of the tumor-rejection antigen SARTl in brain tumors. Int J Cancer 83:760-764, 1999
23) Irani DN, Lin KI, Griffin DE:Regulation of brain-derived T cells during acute central nervous system inflammation. J Immunol 158:2318-2326, 1997
P.139 掲載の参考文献
4) Knerich R, Robustelli della Cuna G, Butti G, et al:Chemotherapy plus immunotherapy for patients with primary and metastatic brain tumors. J Neurosurg Sci 29:19-24, 1985
5) 永井政勝:悪性脳腫瘍に対する Human Fibroblast Interferon (BM532) の臨床効果. 日癌治 24:638-646, 1989
6) Wakabayashi T, Hatano N, Kaj ita Y, et al:Initial and maintenance combination treatment with interferon-β, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neuro-Ooncol 49:57-62, 2000
7) Dillman RO, Shea WM, Tai F, et al:Interferon-α 2a and 13-cis-retinotic acid with radiation treatment for higr-grade glioma. Neuro-Oncol 3:35-41, 2001
8) 松谷雅生:脳腫瘍のBRM療法, 高倉公朋監修:Annual Review 神経, 中外医学社. 東京, p170-175, 1995
9) Yung WKA, Prados M, Levin VA, et al:Intravenous recombinant interferon β in patients with recurrent malignant gliomas:A phase 1/II study. J Clin Oncol 9:1945-1949, 1991
10) Buckner JC, Schomberg PJ, McGinnis WL, et al:A phase III study of radiation therapy plus carmustine with or without recombinant interferon-αin the treatment of patients with newly diagnosed high-grade glioma. Cancer 92:420-423, 2001
11) Natsume A, Tsujimura K, Mizuno M, et al:IFN-β gene therapy induces systemic antitumor imuunity against malignant glioma. J Neuro-Oncol 47:117-124, 2000
12) Takahashi H, Herlyn D, Atkinson B, et al:Radioimmunodetection of human glioma xenografts by monoclonal antibody to epidermal growth factor receptor. Cancer Res 47:3847-3850, 1987
14) Bender H, Takahashi H, Adachi K, et al:Immunotherapy of human glioma xenografts with unlabeled, 1311, 1251-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 52:121-126, 1992
15) Takahashi H, Adachi K, Yamaguchi F, et al:Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates. Anticancer Res 19:4154-4156, 1999
17) 恵 答美, 高橋 弘, 大上千鶴子:マウス同系悪性脳腫瘍 203-glioma 細胞に対する免疫賦活剤 ubenimex の抗腫瘍効果. Biotherapy 10:1187-1192, 1996
18) Takahashi H, Nakazawa S:Antitumour effect of Juzen-Taiho-To, a Kampo medicine, for transplanted malignant glioma. Int J Immunotherapy Xl:65-69, 1995
19) 宮上光祐, 片山容一:T細胞サブセット, NK 活性からみた脳腫瘍に対する十全大補湯の免疫賦活作用. Biotherapy 14:641-646, 2000
P.142 掲載の参考文献
1) 金森利至ほか:インターフェロンβの基礎的研究-第3報-抗腫瘍作用機序. 癌と化学療法 13:2111-2116, 1986
2) Schultz RM, Chirigos MA:Similarity among factors that render macrophages tumoricidal in lymphokine and interferon preparation. Cancer Res 38:1003-1007, 1978
3) 高倉公朋:膠芽腫に対するインターフェロンβ髄腔内投与の臨床効果. Biotherapy 4:215-221, 1990
4) 永井政勝:悪性脳腫瘍に対するインターフェロンの局所投与の効果. Biotherapy 5:1752-1759, 1991
5) 高澤徳彦:TNF/LT, 宮園浩平, 菅村和夫編:サイトカイン・増殖因子, 羊土社, 東京, p166-167, 1995
8) 石井直人:IL-2, 宮園浩平, 菅村和夫編:サイトカイン・増殖因子, 羊土社, 東京, p20-21, 1995
11) Leonard JP, et al:Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541-2548, 1997
13) Kikuchi T, et al:Antitumor activity of interleukin 2 producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the centralnervous system. lnt J Cancer 80:425-430, 1999
16) 岡村春樹ほか:インターロイキン18. 臨床免疫 29:683-689, 1998
18) Osaki T, et al:IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma-and IL-12-independent antitumor effects. J Immunol 160:1742-1749, 1998

第5章 化学療法

P.150 掲載の参考文献
4) Glioma Meta-analysis Trialists (GMT) Group:Chemotherapy in adult high-grade glioma:a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011, 2002
6) Huncharek M, Muscat J, Geschwind JF:Multi-drug versus single agent chemotherapy for high grade astrocytoma;results of a meta-analysis. Anticance Res 18:4693, 1998
8) Randomized trial of procarbazine, lomustine, andvincristine in the a adjuvant treatment of high-grade astrocytoma:a Medical Research Council trial. J Clin Oncol 19:509, 2001
18) van den Bent MJ, Taphoom MJ, Brandes AA, et al:EORTC brain tumor group study 26971:first line chemotherapy with temozolomide in recurrent oligodendroglial tumors;a phase II study. Proc Am Soc Clin Oncol abstract 285, 2002
20) Antonadou D, Paraskevaides M Coliarakis N, et al:Temozolomide Enhances Radiation Treatment Efficacy in Brain Metastases:a Randomized Phase II Study. Proc Am Soc Clin Oncol abstract 224, 2001
23) Levin VA, Edwards MS, Wright DC, et al:Modified procarbazine, CCNU and vincristine (PCV_3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-241, 1980
P.155 掲載の参考文献
1) Kleihues P, Cavenee WK eds:Pathology and Genetics of Tumors of the Nervous System, IARC press, Lyon, 2000
4) Caimcross JG, Macdonald DR:Oligodendroglioma:a new chemosensitive tumor. J Clin Oncol 8:2090-2091, 1990
5) Caimcross JG, Ueki K, Zlatescu MC et al:Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
6) Smith JS, Perry A, Borell TJ et al:Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645 2000
7) Ino Y, Betensky RA, Zlatescu MC et al:Molecular subtypes of anaplastic oligodendroglioma:implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001
11) Watanabe K, Tachibana O, Sata K et al:Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-223, 1996
12) Ueki K, Nishikawa R, Nakazato Y et al:Correlation of histology and molecular genetic analysis of lp, 19q, 10q, TP53, EGFR, CDK4 and CDKN2A in 91 diffuse gliomas. Clin Cancer Res 8:196-201, 2002
14) Schmidt MC, Antweiler S, Urban N et al:Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol. 61:321-328, 2002
15) Kappelle AC, Postma TJ, Taphoorn MJ et al:PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56:118-120, 2001
P.162 掲載の参考文献
1) Heideman RL, Cole DE, Balis F et al:Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients:evidence for dose dependent plasma clearance of thiotepa. Cancer Res 49:736-741, 1989
5) Vassal G, Deroussent A, Hartmann O et al:Dose dependent neurotoxicity of high-dose busulfan in children:a clinical and pharmacological study. Cancer Res 50:6203-6207, 1990
6) Friedman HS, Colvin OM, Skapek SX et al:Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48:4189-4195, 1988
8) Zeltzer PM, Boyett JM, Finlay JL:Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children:conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
13) Gururangan S, Dunkel IJ, Goldman S et al:Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 16:2486-2493, 1998
16) Baranzelli MC, Pichon F, Patte C et al:High-dose etoposide and thiotepa for recurrent intracranial germ cell tumors. Med Pediatr Oncol 31:256 P2, 1998
17) Tada T, Takizawa T, Nakazato F et al:Treatment of intracranial nongemminomatous gemm-cell tumor by high-dose chemotherapy and autologous stem-cell rescue. J Neurooncol 44:71-76, 1999
18) Bouffet E, Mottolese C, Jouvet A et al:Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 33:91-95, 1999
22) Mason WP, Goldman S, Yates AJ et al:Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol 37:135-143, 1998
P.168 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan:Report of Brain Tumor Registry of Japan (1969-1993), 19th ed. Neurol Med Chir (Tokyo) 40 (Suppl), 2000
10) 大西丘倫, 吉峰俊樹:CNS リンパ腫に対する治療の進歩-Methotrexate 大量療法より-脳外誌 10:135-141, 2001
11) Pitman SW, Frei EIII:Weekly methotrexate-calcium leucovorin rescue:Effect of alkalinization on neurotoxicity:Pharmacokinetics in the CNS; and use in CNS non-AHodgkin's lymphoma. Cancer Treat Rep 61:695-701, 1977
12) Coldman AJ, Goldie JH:Impactof dose-intensity chemotherapy on the develpopement of permanent resistance. Semin Oncol 14:29-33, 1987
P.175 掲載の参考文献
3) Brem S, Zagzag D, Tsanaclis A et al:Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 137:1121-1142, 1990
8) Kerbel R, Viloria-Petit A, Okada F et al:Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4:286-295, 1998
12) O'Reilly M, Holmgren L, Chen C et al:Angiostatin induces and sustains dormancy of human primary tmmors in mice. Nat Med 2:689-692, 1996
13) O'Reilley M, Boehm T, Shing Y et al:Endostatin:and endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
16) Sillis A J, Williams J, Tyler B et al:Squalamine inhibits angiogenesis and solid tumor growth in vivo and preturbs embryonic vasculature, Cancer Res 58:2784-2792, 1998
20) Brem H, Ehrlich P, Tsakayannis D et al:Delay of wound healing by the angiogenesis inhibitor TNP-470. Surg Forum 48:714-716, 1997
P.179 掲載の参考文献
5) Price A, Shi Q, Morris D, Wilcox ME, Brasher PM, Rewcastle NB, Shalinsky D, Zou H, Appelt K, Johnston RN, Yong VW, Edwards D, Forsyth P:Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrixmetalloproteinase inhibitor AG3340. Clin Cancer Res 5:845-854, 1999
P.185 掲載の参考文献

第6章 放射線治療

P.190 掲載の参考文献
1) 中川恵一:高精度放射線治療への道オーバービュー. 現代医療 33:2570-2576, 2001
2) 高倉公朋:Radiosurgery の現況と今後の展望-overview-. 別冊医学のあゆみ, Radiosurgery の最前線-現況と展望 (堀 智勝監修). 医歯薬出版, pp1-5, 2002
3) 松尾孝之, 柴田尚武:Linac radiosurgery. 別冊医学のあゆみ, Radiosurgery の最前線-現況と展望 (堀 智勝監修). 医歯薬出版, pp11-18, 2002
4) 森内秀佑, 丸野元彦, 井上武宏, ほか:サイバーナイフ. 定位的放射線治療 (高倉公朋監修). メジカルビュー社, pp106-111, 2000
5) 笹井啓資:Information Technology 時代の頭蓋内病変に対する定位放射線照射. 画像情報Medical 33:1158-1162, 2001
6) 植松 稔:体幹部腫瘍に対するCTガイド下の三次元定位放射線治療-とくに早期肺癌-. 別冊医学のあゆみ, Radiosurgeryの最前線-現況と展望 (堀 智勝監修). 医歯薬出版, pp101-103, 2002
8) 白土博樹, 青山英史, 飛騨一利, ほか:直線加速器を用いた定位放射線照射. 脳神経外科, 30:579-591, 2002
9) 丸野元彦, 井上武宏, 吉峰俊樹:サイバーナイフによる脊髄疾患への定位的放射線治療. 別冊医学のあゆみ, Radiosurgeryの最前線-現況と展望 (堀 智勝監修). 医歯薬出版, pp97-99, 2002
10) 播野和男, 成田雄一郎, 酒井光弘, ほか:I強度変調放射線治療IMRT. 画像情報 Medical 33:1172-1177, 2001
11) 溝脇尚志:生物的画像と強度変調放射線治療. 画像情報 Medical 33:1178-1183, 2001
13) Grosu AL, Weber WA, et al:First experience with I-123-alpha-methyl-tyrisine SPECT in the 3-D radiation treatment plaiming of brain gliomas. lnt J Radia Oncol Biol Phys 47:517-526, 2000
15) Pirzkall A, McKnight TR, et al:MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radia Oncol Biol Phys 50:915-928, 2001
17) 村垣善浩:Photon Radiosurgery System. 定位的放射線治療 (高倉公朋監修). メジカルビュー社, pp124-135, 2000
18) 井上俊彦:小線源治療-前立腺癌組織内照射-. 現代医療33:2591-2596, 2001
19) 前林勝也, 辻井博彦:粒子線治療. 現代医療 33:2597-2601, 2001
P.197 掲載の参考文献
4) Yamanaka K:Prognostic factors for brain metastasis from lung cancer after gamma knife radiosurgery. Osaka city medicaljournal (JAPAN) 45 (1):p45-59, 1999
14) Noren G:Long-term complications following gamma knife radiosurgery of vestibular schwannomas. Stereotactic and functional neurosurgery (SWITZERLAND) 70 Suppl 1:p65-73, 1998
16) Iwai Y, Yamanaka K, Nakajima H, Yasui T, Kishi H:Gamma knife radiosurgery for skull base meningiomas:the treatment results and patient satisfaction expressed in answers to a questionnaire. No shinkei geka (JAPAN) 28 (5):p411-415, 2000
P.202 掲載の参考文献
1) Betti O, Derechinsky V:Multiple-beam stereotaxic irradiation. Neurochirurgie 29 (4):295-298, 1983
4) 白土博樹, 井須豊彦, 清水幸彦, 西岡 健, 野中 雅, 阿部 悟, 松村茂樹, 清水 匡, 市村 亘, 鈴木恵士郎, 南部敏和:リニアック脳定位照射法の Prospective Dose-Escalation Study. 脳神経外科 21 (12), 1993
18) Nishibori T, Shirato H, Aoyama H:Three-dimensional conformal radiotherapy (3DCRT) for astrocytic tumors involving eloquent area in children and young adults. Neuro-Oncology in press.
P.209 掲載の参考文献
P.214 掲載の参考文献
P.219 掲載の参考文献
6) Wittig A, Hideghety K, Paquis P, et al:Current clinical results of the EORTC-study 11961. In:Research and development in neutron capture therapy, Monduzzi, 1117-1122, 2002
7) Kageji T, Nagahiro S, Uyama S, et al:Clinical review of BNCT using mixed neutron beam in patients with malignant glioma. In:Research and development in neutron capture therapy, Monduzzi, 1085-1091, 2002
8) Ono K, Masunaga S, Kinashi Y, et al:Results of BNCT to brain tumor in KUR. In:Research and development in neutron capture therapy, Monduzzi, 1097-1100, 2002
9) Matsumura A, Yamamoto T, Shibata Y, et al:Intraoperative boron neutron capture therapy using thermal/epithermal mixed beam. In:Research and development in neutron capture therapy, Monduzzi, 1073-1078, 2002
10) Burian J, Marek M, Rataj J, et al:Report on the first patient group of the phase I BNCT trial at the LVR-15reactor. In:Research and development in neutron capture therapy, Monduzzi, 1107-11112, 2002
11) Chanana AD, Capala J, Chadha M, et al:Boron neutron capture therapy for glioblastoma multiforme:Interim results from the phase I/II dose-escalation studies. Neurosurgery 44:1182-1193, 1999
12) Joensuu H, Kankaanranta L, Seppala, et al:Preliminary results of the first Finnish BPA-based BNCT trial on primary glioblastoma. In:Research and development in neutron capture therapy, Monduzzi, 1093-1096, 2002
13) Capala J, Skold K, Stenstam BH, et al:Clinical BNCT studies in Sweden. In:Research and development in neutron capture therapy, Monduzzi, 1101-1106, 2002
14) 小野公二:悪性神経膠腫の硼素中性子捕捉療法 (原子炉医療), 脳神経外科速報 6:429-434, 1996
15) Matsumura A, Shibata Y, Yamamoto T, et al:The University of Tsukuba BNCT research group:first clinical experiences at JAERI. In:Advances in Neutron Capture Therapy-Vol. 1 Medicine and physics, Larsson, Crawford and Weinreich ed., Elsevire, pp46-50, 1997
17) Kumada H, Kishi T, Hori N, et al:Development of the multi-leaf collimator for neutron capture therapy. In:Research and development in neutron capture therapy, Monduzzi, 115-120, 2002
P.226 掲載の参考文献
1) Mizoe J, Aoki Y, Morita S et al:Fast neutron therapy for malignant gliomas-results from NIRS study. Strahlenther Onkol 169:222-227, 1993
5) 溝江純悦, 辻井博彦:大川智彦, 田中良明, 佐々木武仁編:重粒子線治療, 癌・放射線療法 2002, 篠原出版新社, 東京, p357-368, 2002
8) Loeffler JS, Smith AR, Suit HD:The Potential Role of Proton Beams in Radiation Oncology. Seminars in Oncology 24:686-695, 1997

第7章 温熱療法

P.230 掲載の参考文献
5) 畑山 巧:温熱療法の細胞生物学的基礎と温熱耐性の分子機構. 最新医学 49:2138-2146, 1994
9) Ohnishi T, Matsumoto H, Wang X et al:Restration of p53-dependent apoptosis in the cells bearing the mutant p53 gene by glycerol. Int J Radiat Biol 75:1095-1098, 1999
11) Huang Q, Hu JK, Lohr F et al:Heat-induced gene expression as a novel targeted cancer gene therapy. Cancer Res 60:3435-3439, 2000
13) Eddy HA, Salazar OM, Amin PP et al:Acute histopathological changes in brain following interstitial hyperthermia and irradiation. Endocurietherapy/Hyperthermia Oncol 8:27-40, 1992
15) Takahashi S, Tanaka R, Watanabe M et al:Effects of Whole-Body Hyperthermia on the Canine Central Nervous System. Int J Hyperthermia 15:203-216, 1999
16) Sneed PK, Stauffer PR, McDermott MW et al:Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:287-295, 1998
17) 田中隆一, 高橋英明, 宇塚岳夫:脳腫瘍の温熱療法悪性グリオーマの RF 組織内加温法, 加納永一監修:集学的癌治療の研究と臨床, 篠原出版新社, 東京, p. 305-313, 2002
18) Takahashi H, Tanaka R, Uzuka T et al:Clinical results of hyperthermia for brain tumors, Tanaka R, ed:Advances in Hyperthermic Oncology 2000, Koko-do, Niigata, p132-136, 2001
19) Uzuka T, Tanaka R, Takahashi H et al:Planning of hypenhemmic treatment for malignant glioma using computer simulation. Int J Hypertheumia 17:114-122, 2001
20) Stea B, Rossman K, Kittelson J et al:Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas:A comparative survival analysis. Int J Radiat Oncol Biol Phys 30:591-600, 1994
22) 若林俊彦, 中原紀元, 国本圭市ほか:磁性微粒子を用いた細胞内温熱療法の検討, 田渕和雄, 白石 哲也編集:ポストシークエンス時代における脳腫瘍の研究と治療, 九州大学出版会, 福岡, p493-496, 2002
25) Morita K, Tanaka R, Kakinuma K et al:Combinationtherapy of rat brain tumors using localized interstitial hyperthermia and intra-arterial chemotherapy. Int J Hypenhemmia. 2002, in press
26) Kakinunma K, Tanaka R, Takahashi H et al:Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hypenhemmia. J Neurosrug 84:80-84, 1996
P.238 掲載の参考文献
4) 小林達也, 木田義久, 松井正顕ほか:悪性脳腫瘍の組織内加温法-インプラントヒーティングシステムを用いて. 医学のあゆみ 149:1-2, 1989
5) Takahashi H, Tanaka R, Nakajima T et al:Interstitial hyperthermia using 13.56 MHz radiofrequency for malignant brain tumors. Hyperthermic Oncol 1:394, 1992
6) 田中隆一, 高橋英明, 中島 拓ほか:脳腫瘍の温熱療法:組織内加温システムの開発と臨床応用. Neurosurgeons 14:129-136, 1995
7) 高橋英明, 田中隆一, 渡辺正人ほか:脳腫瘍に対する温熱治療のための温度分布シミュレーション-二次元有限要素解析による computer simulation-. Jpn J Hyperthermic Oncol 11:356-363, 1996
8) Uzuka T, Tanaka R, Takahashi H et al:Planning of hypenhemmic treatment for malignant glioma using computer simulation. Int J Hyperthermia 17:114-122, 2001
10) 松本健五, Stauffer PR, Fike JR ほか:悪性脳腫瘍対する温熱療法の基礎的研究-加温装置の開発および正常イヌ脳に対する加温効果の検討. 脳神 経外科 14:965-972, 1986
11) Takahashi S, Tanaka R, Watanabe M et al:Effects of whole-body hyperthermia on the canine central nervous system. Int J Hyperthermia 15:203-216, 1999
P.245 掲載の参考文献
1) Wakabayashi T, Yoshida J, Mizuno M, Sugita K, Itoh K Tadokoro M, Oshima M:Radioimmunolocahzation of human brain tumor:Fundamental studies with indium-111 labeled monoclonal antibody G-22. Brain Tumor Pathology 11 (2):177-180, 1994
2) Le B, Shinkai M, Kitade T, et al:Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J Chem Eng Jpn 33:821-826, 2000
3) 若林俊彦:モノクローナル抗体結合マグネタイトによる特異的脳腫瘍画像診断への応用. 医療科学社, Innervision. vol 12 (8):30, 1997
4) Suzuki M, Honda H, Kobayashi T, Wakabayashi T, Yoshida J, Takahashi M:Development of a target-directed magnetite resonance contrast agent using monoclonal antibody-conjugated magnetite particles. Brain Tumor Pathol 13:127-132, 1996
5) 若林俊彦, 吉田 純, 柳瀬 貢, 鈴木基司, 新海政重, 本多裕之, 小林 猛, 高橋昌哉:抗体結合マグネタイトによる悪性 gliomaに対する特異的温熱療法の開発神経免疫研究 vol 8:289-294, 1995
8) Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T:Intracellular hyperthenmia for cancer using magnetite cationic liposomes:An in vivo study, Jpn. J. Cancer Res 89:463-469, 1998
13) Walker AE and CV Burton:Radiofrequency telethermocoagulation. J. Amer. Mec. Ass 197:700-704, 1986
P.251 掲載の参考文献
1) Sugiyana K, Sakai T, Fujishima I, et al:Stereotactic interstitial laser-hyperthenmia using Nd-YAG laser, Stereotact Funct Neurosurg 54-55:501-505, 1990
3) 黒田輝:MRI による脳内温度分布の非侵襲画像計測, 高倉公朋監修:脳神経外科の最先端 NO.2, 先端医療技術研究所, 東京, p226-233, 2000
4) Stollberger R, Ascher PW, Huber D, et al:Temperature monitoring of interstitial thermal tissue coagulation using MR phase images, J Magn Res Imag 8:188-196, 1997
11) Nolsoe C, Torp-pedersen S, Olldag E, et al:Bare fiber low power Nd-YAG laser interstitial hyperthermia. Comparison between diffuser tip and non-modified tip. An in vitro study, Laseres Med Sci 7:1-7, 1992
13) Straube T, Kahn T:Themial therapies in interventional MR imaging:Laser, Neuroimaging Clin N Am 11:749-57, 2001

第8章 切除率向上のための新技術

P.258 掲載の参考文献
1) The Commitee of Brain Tumor Registry of Japan:Report of brain tumor registry of Japan (1969-1993) 10th ed. Neurol Med Chir (Tokyo) 40:49-92, 2000
3) 嘉山孝正:脳の先端イメージングと脳神経外科臨床. Medical imaging technology 17 (1):51-55, 1999
5) 嘉山孝正, 佐藤慎哉:Awake surgery による言語野の決定. 脳と神経 53 (2):151-160, 2001
6) 嘉山孝正:脳内腫瘍性病変に対するジャイレクトミー法. メディカル朝日 27 (8):34-37, 1998
7) 佐藤慎哉, 嘉山孝正:グリオーマの手術. 脳神経外科ジャーナル 11 (8):521-529, 2002
8) 兜 正則, 久保田紀彦, 古林秀則ほか:脳神経外科手術のためのレール方式移動CTスキャナによるCT撮影システム. 脳と神経 50:1003-1008, 1998
9) 黒岩敏彦, 梶本宜永, 太田富男:蛍光色素の脳神経外科手術への応用. 高倉公朋 監修:先端医療シリーズ 6・脳神経外科脳神経外科の最先端 No2. 東京, 最先端医療研究所, 334-337, 2000
11) 久保長生, 村垣善浩, 伊関 洋ほか:Clinical evaluation of intraoperative radiotherapy using photon radiosurgery system for brain tumors. 癌と化学療法 25 (9):1348-1351, 1998
13) 渡辺英寿:高次脳機能のモニタリング. Clinical neuroscience 20 (9):986-988, 2002
14) 梶本宜永, 市岡従道, 宮武伸一ほか:光ファイバーを用いた蛍光標識腫瘍センサーの開発. 田渕和雄, 白石哲也編:ポストシークエンス時代における脳腫瘍の研究と治療, 福岡市, 九州大学出版会, 311-316, 2002
15) 中村雅也, 戸山芳昭, 岡野栄之:損傷脊髄への神経幹細胞移植. 実験医学 20 (9):1301-1306, 2002
P.265 掲載の参考文献
1) Kuroiwa T, Kajimoto Y, Ohta T:Usefulness of a new fluorescein operative microscope. 11th International Congress of Neurological Surgery 1641-1646, 1997
3) 黒岩敏彦, 梶本宜永, 小畑仁司ほか:手術用蛍光顕微鏡を用いた悪性グリオーマの手術. 柴田尚武編, グリオーマの外科, メディカ出版, 大阪, p46-51, 1998
6) 黒岩敏彦, 梶本宜永, 太田富雄:蛍光色素の脳神経外科手術への応用. 高倉公朋監修:脳神経外科の最先端, 先端医療技術研究所, 東京, p334-337, 2000
7) 黒岩敏彦, 宮武伸一:大脳半球星状細胞腫の手術. 脳外 29:107-118, 2001
8) 金子貞男:脳腫瘍に対する光モニタリング-ALA induced Pp IX による術中脳腫瘍蛍光診断-脳外 29:1019-1031, 2001
12) Stummer W, Stocker S Wagner S, et al:Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42:518-525, 1998
19) 黒岩敏彦, 平野朝雄, Josefina F. Llena:Glioblastoma の血管に関する光顕的検討. Neurol Med Chir (Tokyo) 27:717-723, 1987
20) 梶本宜永, 三宅裕治, 黒岩敏彦:LabVIEW の臨床応用. 高倉公朋監修:脳神経外科の最先端, 先端医療技術研究所, 東京, p327-333, 2000
P.273 掲載の参考文献
11) 隈部俊宏, 中里信和, 鈴木匡子ほか:運動領野周 辺神経膠腫に対する手術-術前解剖学的及び機能的マッピングの融合とニューロナビゲーションシステム及び術中マッピング併用による運動機能温存 手術-脳外誌 10:56-64, 2001
12) 隈部俊宏, 中里信和, 岩崎真樹ほか:中心前回に 存在する神経膠腫の手術. 脳外誌 11:271-277, 2002
P.274 掲載の参考文献
P.281 掲載の参考文献
3) Report of brain tumor registry of Japan (1969-1993) 10th edition. Neurologia Medico-Chirurgica (Tokyo) 40 (supplement):1-106, 2000
10) 国沢卓之, 尾崎 眞:私の麻酔法, 術中に覚醒をさせる手術の麻酔-Awake craniotomy-.A net 6-3:24-27, 2002
13) 星田 徹, 榊 寿右:皮質電気刺激による脳機能マッピング. 高倉公朋 (編), 脳神経外科の最先端 NO.2 21世紀の新領域とニューテクノロジー, 先端医療技術研究所, 東京, pp261-pp268, 2000
14) 村垣善浩, 平沢研一, 山根文孝, 今村 強, 丸山 隆志, 久保長生, 堀 智勝:長期硬膜下電極埋め込みによる Mapping を利用した Eloquent Area 近傍Glioma摘出術. 嘉山孝正編 Advanced Technology を用いた脳腫瘍の外科, メディカ出版, 大阪, pp140-pp148, 2001
17) Taniguchi M, Nadstawek J, Langenbach U, et al:Effects of four intravenous anesthetic agents on motor evoked potentials elicited by magnetictranscranial stimulation. Neurosurgery 33:407-415;discussion 415, 1993

第9章 ナビゲーション手術とロボット手術

P.287 掲載の参考文献
3) Moesges R, Schloendorff G:A new imaging method for intraoperative therapy control in skull basesurgery. Neurosurg Rev 11:245-247, 1988
6) Watanabe E, Kosugi Y, Intraoperative neuronavigator system in neurosurgery and computer surgery. in Fujino T. (ed);Simulation and computer-aided surgery, John Wiley & Sons, Chichester, pp 157-162, 1993
7) 渡辺英寿, 小杉幸夫:ニューロナビゲータ, nanoGIGA 2:1807-1811, 1993
12) 渡辺英寿, 真柳佳昭, 金子 裕:ニューロナビゲータと脳磁図による中心溝の決定, 脳神経 45:1027-1032, 1993
P.292 掲載の参考文献
P.302 掲載の参考文献
1) 阿部雅光, 鵜殿弘貴, 田渕和雄ほか:ナビゲーションシステムを利用した経蝶形骨洞手術. 脳神経外科 29:31-38, 2001
6) 寺本 明, 高倉公朋:下垂体腫瘍の手術-経蝶形骨法の実際. Clin Neurosci 2:344-, 1984
7) 有田和徳, 魚住 徹, 矢野 隆ほか:Sublabial Transspenoidal Approach 後の口部合併症と Endonasal Transsphenoidal Approach の利点. 脳神経外科 22:119-124, 1994
8) 栗坂昌宏, 佐田泰夫, 本田信也ほか:下垂体腺腫に対する Endonasal Unilateral Transsphenoidal Approach (EUSTA) 法. 手術 44:1781-1786, 1990
9) 北野昌彦, 種子田 護:内視鏡を応用した経蝶形骨下垂体腺腫摘出術. 脳神経外科25 (3):197-203, 1997
14) 黒木 亮, 嘉山孝正:下垂体腺腫への内視鏡的アプローチ-経鼻孔経蝶形骨洞手術における種々の工夫と進歩-. 脳神経外科速報 10:721-730, 2000
15) 黒木 亮, 嘉山孝正:神経内視鏡下側脳室へのアプローチ, 顕微鏡下手術のための脳神経外科解剖 XIV-脳室系の立体解剖-, 東京:サイメッド・パブリケーションズ. pp91-98, 2002
P.308 掲載の参考文献
2)橋詰清隆, 田中達也, 国本雅之ほか:画像誘導手術支援装置を用いた難治性てんかんの手術. 脳外 25:329-335, 1997
5) 須賀俊博, 内田桂太, 香川茂樹ほか:腹側髄外性発育を呈した脳幹部神経膠腫の 1 手術例. 脳外 23:1037-1042, 1995
P.313 掲載の参考文献
1) Cain P, Kazanzides P, Zuhars J, et al:Safety considerations in a surgical robot. Biomed Sci Instrum 29:291-294, 1993
2) 菅野伸彦, 西井 孝, 原口圭司, ほか:新しい医療技術-ロボット手術. 整形・災害外科 43:1333-1337, 2000
4) Cadiere GB, Himpens J, Germay O, et al:Feasibility of robotic Iaparoscopic surgery:146 cases. World J Surg 25:1467-1477, 2001
5) 小澤壯治, 古川俊治, 若林 剛, ほか:内視鏡下ロボット手術. 消化器内視鏡 14:361-366, 2002
6) 橋爪 誠, 富川盛雅, 島田光生, ほか:da Vinci を用いたロボット手術. 臨床外科 57:39-45, 2002
7) Detter C, Boehm D, Reichenspurner H, et al:Robotically-assisted coronary artery surgery with and without cardiopulmonary by pass-from first clinical use to endoscopic operation. Med Sci Monit 8:118-123, 2002
8) 渋谷和彦, 阿部 永, 乙供 茂, ほか:ZEUS? を用いたロボット手術. 臨床外科 57:33-37, 2002
10) Okudera H, Kobayashi S:Techniques for exposur ln open neurosurgery. In:Andrews RJ, ed., Intraoperative Neuroprotection, Wiliams & Wilkins, Baltimore, p445-470, 1996
11) 奥寺 敬, 小林茂昭, 村岡紳介, ほか超微小手術システムHUMAN system開発の経緯と将来像. 先端医療5:94-96, 1998
12) Kan K, Nishizawa K, Tajima F, et al:Microscopic-manipulator system for minimally invasive neurosurgery. in Lemke HU, Vannier MW, Inamura K, Farman AG, eds, CAR:98. pp594-598, Elsevier, Amsterdam, 1998
13) 奥寺 敬:微小手術操作支援システムHUMAN systemによるmicrosurgery. 高倉公朋 (監修) 先端医療シリーズ 6:脳神経外科No.2 21世紀の新領域とニューテクノロジー, 先端医療技術研究所, 東京, 58-62, 2000

第10章 画像診断・検査

P.318 掲載の参考文献
1) 興梠征典, 高橋睦正, 生塩之敬:グリオーマの画像診断. 生塩之敬, 山浦晶編, グリオーマ, 三輪書店, 49-64, 1997
2) 矢村正行, 生嶋一朗, 興梠征典, 高橋睦正:臨床 Review Functional Imaging (機能画像) Cancer Frontier, Vol. 3:81-86, 2001
8) Sugahara T, Korogi Y, Tomiguchi S, et al:Posttherapeutic intraaxial brain tumor:the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR 21:901-909, 2000
10) Desprechins B, Stadnik T, Koerts G, et al:Use of diffusion-weighted MR imaging in differential diagnosis between intracerebral necrotic tumors and cerebral abscesses 20:1252-1257, 1999
11) Sugaliara T, Korogi Y, et al:Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. JMRI 9 (2):53-60, 1999
14) 小川誠二:Functional magnetic resonance imaging. 神経進歩38:309-318, 1994
15) Rao SM, Binder JR, Hammeke TA, et al:Somatotopic mapping of the human primary motor cortex with functional magnetic resonance imaging. Neurology 45:919-924, 1993
22) Holodny AI, Schulder M, Liu WC, et al:The effect of brain tumor on BOLD functional MR imaging activation in the adjacent motor cortex:Implications for image-guided neurosurgery. AJNR 21:1415-1422, 2000
23) Schreiber A, Hubbe U, Ziyeh S, et al:The influence of gliomas and nonglial space-occupying lesions on blood-oxygen-level-dependent contrast enhancement. AJNR 21:1055-1063, 2000
24) 興梠征典, 高橋睦正, 生塩之敬:神経堤由来腫瘍の画像診断. 生塩之敬, 山浦晶編, 神経堤由来組織の腫瘍性病変, 三輪書店, 29-43, 1999
25) Allen RW, Hamsberger HR, Shelton C, et al:Low-cost high-resolution fast spin-echo MR of acousticschwannoma:an alternative to enhanced conventional spin-echo MR?AJNR Am J Neuroradiol 17:1205-1210, 1996
26) Fukui MB, Weissman JL, Curtin HD, Kanal E:T2-weighted MR characteristics of internal auditory canal masses. AJNR Am J Neuroradiol 17:1211-1218, 1996
27) Stuckey SL, Harris AJ, Mannolini SM:Detection of acoustic schwannoma:use of constructive interference in the steady state three-dimensional MR. AJNR Am J Neuroradiol 17:1219-1225, 1996
28) Curtin HD:Rule out eighth nerve tumor:contrast-enhanced T1-weighted or high-resolution T2-weighted MR? AJNR Am J Neuroradiol 18:1834-1838, 1997
29) Shigematsu Y, Korogi Y, Hirai T, et al:Contrast-enhanced MRI of vestibular schwannomas:phantom and clinical studies. J Comput Assist Tomogr 23:224-231, 199
P.325 掲載の参考文献
P.331 掲載の参考文献
1) 井形昭弘, 朝倉哲彦, 藤元登四郎:脳神経疾患の MRS, 先端医療技術研究所, 1997
2) 山本 徹:MRSの基礎, in井形昭弘, 朝倉哲 彦:脳神経疾患のMRS, 先端医療技術研究所, 1997
3) 藤元登四郎, 辻 隆之, 中野寿彦ほか:健常者の脳の31P化学シフトイメージング法による研究. 日磁医誌 14:1-10, 1994a
4) 藤元登四郎, 朝倉哲彦, 中村克巳:てんかんと MRS, in秋元波留夫, 山内俊雄 編集:てんかん学の進歩, No.3, 岩崎学術出版社, pp 327-357, 1996c
5) NgTC, Evanochko WT, Hiramoto RN, et al::31P-NMR spectroscopy of in vivo tumors. J. Magn. Reson 49:271-286, 1982
6) Asakura T, Sasahira M:Magnetic resomnce spectroscopy and chemical shift imaging of the brain. Neurosciences 20:83-101, 1994
8) 笹平正廣, 朝倉哲彦, 内村公一ほか:脳腫瘍, 脳血管障害の31P chemical shift imaging. CI研究14:517-531, 1992
10) 藤元登四郎, 中村克巳:MRS. 脳神経外科疾患の最先端-QOLの向上のために, 東京, 先端医療技術研究所, 208-217, 1999
11) Younker W, Shi-Jiang Li:Differentiation of metabolic concentration between gray matter and white matter of human brain by in vivo IH magnetic resonance spectroscopy. Magn Reson Med 39:28-33, 1998
13) Gruetter R, Mescher M, Kirsch J, et al:1H MRS ofneurotransmitter GABA in humans at 4 Tesla. In Proceedings:Fifth Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Vol. 2 Vancouver, B. C., Canada:ISMRM:1217, 1997
14) Hetherrinngton HP, Newcomer BR, Pan JW:Measurements of human cerebral GABA at 4. 1T using numerically optimized editing pulses. Magn Reson Med 39:6-10, 1998
15) Yonker W, Shi-Jiang L:Differentiation of Metabolic Concentrations Between Gray Matter and White Matter of Human Brain by in vivo IH Magnetic Resonance Spectroscopy, MRM 39:28-33, 1998
P.336 掲載の参考文献
1) 佐々木真理 (編):MDCT徹底攻略マニュアル, メジカルビュー, 東京, 2002
2) 片田和廣:CT診断の最近の進歩-マルチスライスCTを中心に-. 断映研会誌28:203-209, 2001
3) 佐々木真理:脳神経系におけるマルチスライスCT の有用性と問題点. 断映研会誌29:2002
4) 佐々木真理:脳神経領域におけるMDCTの現状. 新医療2002
5) Katada K, et al:Usefulness of isotropic volumetric data in neuroradiological diagnosis. In Reiser MF (ed) Multislice CT. Springer-Verlag. Berlin 117-119, 2001
6) 片田和廣:MDCTの将来. 佐々木真理 (編):MDCT徹底攻略マニュアル, メジカルビュー, 東京, 228-237, 2002
7) 片田和廣, 藤井直子, 加藤良一, ほか:8列multislice CT advanced Aquilionの臨床経験. 映像情報メディカル 34 (7):52-59, 2002
8) 及川博文:頭部CT, 頭蓋内CTA. 佐々木真理 (編):MDCT徹底攻略マニュアル, メジカルビュー, 東京, 72-83, 2002
9) 赤羽正章, 大友邦:CTの被曝と撮影条件最適化. 画像診断22:318-327, 2002
10) Wintermark M, Maeder P, Verdun FR, et al:Using 80kVp versus 120kVp in perfusion CT measurement of regional cerebral blood flow. AJNR 21:1881-1884, 2000
11) European Guidance on Quality Criteria for Computed Tomography. EUR 16262, EC, 1999 (http://www. drs. dk/guidelines/ct/quality/indexhtm)
12) Yang Y, Nakamori N, Yoshida Y, et al:De-noising of cone beam CT image using wavelet transform. SPIE Proceedings (Image Processing of Medical Imaging) 200
P.340 掲載の参考文献
2) Tohyama T, Lee VM, Rorke LB, et al:Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest 66:303-313, 1992
3) Florenes VA, Holm R, Myklebost O, et al:Expression of the neuroectodermal intermediate filament nestin in human melanomas. Cancer Res 54:354-356, 1994
4) Dahlstrand J, Collins VP, Lendahl U:Expression ofthe class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52:5334-5341, 1992
6) Shaw G, Weber I (:The structure and development of the rat retina:an immunofluorescence microscopical study using antibodies specific for intermediate filament proteins. Eur J Cell Biol 30:219-232, 1983
9) Carden MJ, Trojanowski JQ, Schlaepfer WW, et al:Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation pattems. J Neurosci 7:3489-3504, 1987
11) Molenaar WM, Baker DL, Pleasure D, et al:The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. Am J Pathol 136:375-382, 1990
24) Takagi M, Matsuoka Y, Kurihara T, et al:Chmadrin:anovel Ki-67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure. J Cell Sci 112 Pt 15:2463-2472, 1999
25) Gerdes J, Lemke H, Baisch H, et al:Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
27) Figarella-Branger D, Civatte M, Bouvier-Labit C et al:Prognostic factors in intracranial ependymomas in children. J Neurosurg 93:605-613, 2000
33) Watanabe K, Sato K, Biemat W, et al:Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3:523-530, 1997
34) Rasheed BK, McLendon RE, Herndon JE, et al:Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-1330, 1994
38) Pollack IF, Finkelstein SD, Burnham J, et al:Age and TP53 mutation frequency in childhood malignant gliomad:results in a multi-institutional cohort. Cancer Res 61:7404-7407, 2001
42) Reifenberger G, Liu L, Ichimura K, et al:Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739, 1993
44) Olson JJ, Barnett D, Yang J, et al:Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4:215-222, 1998
46) Korshunov A, Golanov A, Timirgaz V:p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance:an analysis of 103 cases. Acta Neuropathol (Berl) 102:271-277, 2001
48) Schmidt EE, Ichimura K, Reifenberger G, et al:CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321-6324, 1994
61) Bostrom J, Cobbers JM, Wolter M, et al:Mutation of the PTEN (MMAC 1) tumor suppressor gene in asubset of glioblastomas but not in meningiomaswith loss of chromosome arm 10q. Cancer Res 58:29-33, 199862) Duerr EM, Rollbrocker B, Hayashi Y, et al:PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259-2264, 1998
63) Lin H, Bondy ML, Langford LA, et al:Allelic deletion analyses of MMAC//PTEN and DMBTI loci in gliomas:relationship to prognostic significance. Clin Cancer Res 4:2447-2454, 1998
65) Raffel C, Frederick L, 0:Fallon JR, et al:Analysis of oncogene and tumor suppressor gene alterationsin pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 5:4085-4090, 1999

第11章 治療薬に関する最新情報

P.348 掲載の参考文献
1) Stevens MEG, Hickman JA, Langdon SP, et al:Antitumor activity and phamiacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1, 2, 3, 5-tetrazin-4 (3H)-one, anovel drug with potential as an altemative to dacarbazine. Cancer Recerch 47:5846-5852, 1987
6) Clin Doc 97045275. A Phase I study of temozolomide in adult patients with advanced cancer stratified by extent of prior therapy. Kenilworth (NJ):Schering-Plough Reserch Institute;1996 Dec
9) Brade M, Hoang-Xuang K, Rampling R, et al:Multicenter phase II trial of temozolomide in patients with gliobaostoma multiforme at first relapse. Ann Oncol 12:259-266, 2001
P.354 掲載の参考文献
1) Julian R Youmans, et al:Neurological Surgery fourth edition:W B Saunders company, USA, p491-492, 1996
3) 片山泰朗, 五十風博中:脳浮腫発現のメカニズムとそのコントロール. Clinical Neuroscience vol 17 no. 5:499-501, 1999
6) Bullock R, Chesnut RM, Clifton G, et al:Guidelines for the management of severe head injury. The brain trauma foundation, NewYork, 1995
7) 山浦晶, 重森稔ほか:重症頭部外傷治療・管理のガイドライン, 日本神経外傷学会機関誌vol.23 No.1:13-25, 2000
9) Lyons MK, Meyer FB:Cerebrospinal Fluid Physiology and the manegement of intracranial pressure. Mayo Clin Proc 65:684-707, 199
12) 田中千賀子, 加藤隆一:NEW薬理学, 南江堂, p139, 332, 410, 417, 435, 1993
13) 日本医薬情報センター編:医療薬日本医薬品集, 第23版, じほう発行, 東京, p562, 563, 850-852, 892, 893, 1111, 1112, 1563-1565, 1720-1723, 1751-1755, 1781-1783, 1883-1885, 1939, 1826-1832, 2083-2985, 2000
15) 柏木史彦, 片山泰朗, 神谷達司ほか:高張溶液 (glycerol) の実験的脳虚血に及ぼす効果-Part3. 投与方法に関する検討. 脳卒中14:583-590, 1992
18) 坂本哲也:脳圧降下薬. 内科82巻4号:676-679, 1998
P.358 掲載の参考文献

第12章 各種製品の臨床評価

P.366 掲載の参考文献
1) Adler JR, Hancock SL:The Neurotron 1000:A system for frameless stereotactic radiosurgery. Perspectives in Neurological Surgery 5:127-133, 1994
4) 塩見 浩也, 井上 武宏, 井上 俊彦ほか:大阪大学におけるCyberKnifeの初期使用経験について. 定位的放射線治療 3:89-95, 1999
5) 井上 武宏, 井上 俊彦:ナロービーム放射線治療-ロボットとトラッキングを用いた新しいナロービーム放射線治療装置-. 癌の臨床 43 (2):221-225, 1997
6) Daniela Schultz-Ertner, et al:Fractionated stereotactic conformal radiation therapy of brain stemgliomas;outcome and prognostic factors. Radiother Oncol 57:215-223, 2000
7) 森木章人, 小野雄弘, 三宅博久ほか:小児全身麻酔下におけるガンマナイフ治療の問題点とその工夫. 定位的放射線治療 4:149-154, 2000
P.369 掲載の参考文献
1) 永井政勝, 新井紀元:悪性脳腫瘍に対するインターフェロン治療の現状と将来. 脳神経外科10 (5):463-476, 1982
2) 永井政勝:悪性脳腫瘍に対するインターフェロンの局所投与の効果. BIOTHERAPY 5 (11):1752-1759, 1991
P.371 掲載の参考文献
4) 奥寺敬:X線透過多目的ヘッドフレーム. THE MIZUHO 8:3-4, 1994
5) 奥寺敬, 京島和彦, 小林茂昭, 清水孝夫:新素材によるX線透過多目的ヘッドフレームの考案. 医科器械学64:282-285, 1994

最近チェックした商品履歴

Loading...